Registry update — unassessed
RESTOR [Rapamycin and Everolimus Study Towards Older Rejuvenation]: An Exploratory PK/PD Study of mTOR Inhibition in Older Human Subjects
Trial registry update: RECRUITING. No results reported in the supplied registry record.
RCTMinor significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Jun 1, 2026 · Discovered: Sep 18, 2026 · Assessed: — · Historical research backfill
What it does not prove
- Whether mTOR inhibition at these doses improves any health outcomes, lifespan, or age-related disease prevention in older humans
- Whether animal model findings showing slowed aging from mTOR inhibitors translate to human benefit
- Whether observed pharmacokinetic/pharmacodynamic targets are clinically meaningful or associated with any therapeutic effect
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Healthy older adults, including both male and female subjects
- Primary outcome
- Safe inhibition of mTOR to levels seen in young healthy persons; pharmacokinetics and pharmacodynamics of mTOR inhibitors in older subjects
- Effect size
- —
- Significance
- Not reported
- Journal
- The University of Texas Health Science Center at San Antonio
- Published
- Jun 1, 2026
Sources
Primary source
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
As people get older, there are changes in their cells and tissues that may affect their ability to function.
This study is focused on one such family of drugs, called mTOR inhibitors, and the investigators' goal is to test two of these drugs, Rapamycin (Sirolimus) and Everolimus (Afinitor), in healthy older adults to find a dose and dose timing that can be used to safely inhibit mTOR to the levels seen in young healthy persons.
The investigators expect that the dose that works well in women may differ from the one that is best in men, so it is important to include both sexes in this research.
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.